Skip to content

ADHD, Gut Problems and Synbiotic

Gut-Brain Study: ADHD, Gastrointestinal Problems and Synbiotic Cap

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07717359
Enrollment
174
Registered
2026-07-21
Start date
2026-09-01
Completion date
2027-12-01
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD, Emotion Regulation Abilities, Gastrointestinal

Keywords

emotion regulation, gastrointestinal health, probiotics, synbiotics, gut-brain axis, ADHD

Brief summary

The scope of this study is to evaluate the impact of a synbiotic product (a combination of probiotic bacteria and prebiotics) on symptoms reported by participants with ADHD. The main focus is to study the efficacy of the synbiotic product as compared to a placebo in improving emotion regulation and gut-health associated symptoms in adults with ADHD.

Interventions

DIETARY_SUPPLEMENTSynbiotic Cap Gut-Brain

Capsules (2 capsules to be ingested once daily during 12 weeks)

OTHERPlacebo

Capsules (2 capsules to be ingested once daily during 12 weeks)

Sponsors

Super Synbiotics AB
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* ADHD-diagnosis * Self-described gastrointestinal problems * Has not previously consumed Synbiotics * Be prepared to avoid supplements with lactic acid bacteria, calcium and vitamin B6, B9, and B12, starting from washout

Exclusion criteria

* Has consumed antibiotics within the previous 6 weeks * Has a serious disease that requires treatment and/or leads to a weakened immune system

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in the total score of Difficulties Regulation Scale 16 (DERS-16) after 12 weeks of intervention.Change from baseline to 12 weeksAll subscales are included in the total score of DERS-16 (Clarity, Goals, Impulse, Strategies and Nonacceptance)

Secondary

MeasureTime frameDescription
Change from baseline in total score for gastrointestinal symptoms (based on a questionnaire) after 12 weeks of intervention.Change from baseline to 12 weeksThe questionnaire consists of a 5-point scale to evaluate the frequency of symptoms such as flatulence, bloating, loose/hard stools, gut pain, feeling sick.
Change from baseline in total score of ASRS v1.1 after 12 weeks of interventionChange from baseline to 12 weeksThe adult ADHD self-report scale consists of 18 items. Change from baseline in the total score for these items will be measured.
Change from baseline in the DERS-16 subscale scores after 12 weeks of intervention.Change from baseline after 12 weeks.The score for each of the DERS-16 subscales (Clarity, Goals, Impulse, Strategies and Nonacceptance) will be analyzed separately
Change from baseline in the frequency of individual gastrointestinal symptoms after 12 weeks of intervention.Change from baseline to 12 weeksThe individual gastrointestinal symptoms include flatulence, bloating, loose/hard stools, gut pain, feeling sick.
Change from baseline in the score of individual ASRS v1.1 items after 12 weeks of intervention.Change from baseline to 12 weeks.The 18 ASRS items will be assessed separately.

Contacts

CONTACTLudvig Ekelund
forskning@supersynbiotics.se+46 8 6601660

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026